PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15730388-0 2005 Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Bleomycin 88-97 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 0-33 15730388-2 2005 In this study, we investigated the role of PAI-1 in bleomycin-induced murine scleroderma. Bleomycin 52-61 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 43-48 15730388-6 2005 The production of active PAI-1 protein in the lesional skin was significantly increased 3 and 4 weeks after bleomycin treatment. Bleomycin 108-117 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 25-30 15730388-8 2005 10 microg of bleomycin was subcutaneously injected to PAI-1-/- and wild type (WT) mice 5 days per week for 4 weeks. Bleomycin 13-22 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 54-59 15730388-10 2005 Dermal thickness and collagen contents in the skin were significantly increased by bleomycin injection in both PAI-1-/- and WT mice, and the rate of increase was similar. Bleomycin 83-92 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 111-116 7544811-8 1995 Taken together, these observations suggest that the induction of PAI-1 and TF gene expression plays and important role in the formation and persistence of extracellular fibrin in bleomycin injured murine lungs. Bleomycin 179-188 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 65-70 14982862-1 2004 Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration. Bleomycin 142-151 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 22-55 14982862-1 2004 Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration. Bleomycin 142-151 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 62-67 14982862-6 2004 Conversely, intratracheal instillation of urokinase into bleomycin-injured PAI-1+/+ mice to activate plasminogen caused a significant increase in HGF within bronchoalveolar lavage and caused less collagen accumulation in the lungs. Bleomycin 57-66 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 75-80 14982862-7 2004 Administration of an anti-HGF neutralizing antibody markedly increased collagen accumulation in the lungs of bleomycin-injured PAI-1-/- mice. Bleomycin 109-118 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 127-132 11104787-1 2000 Mice deleted for the plasminogen activator inhibitor-1 (PAI-1) gene are relatively protected from developing pulmonary fibrosis induced by bleomycin. Bleomycin 139-148 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 21-54 11104787-1 2000 Mice deleted for the plasminogen activator inhibitor-1 (PAI-1) gene are relatively protected from developing pulmonary fibrosis induced by bleomycin. Bleomycin 139-148 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 56-61 10515451-2 1999 Transgenic mice having increased fibrinolytic activity due to genetic deficiency of PAI-1 develop less fibrosis after bleomycin-induced lung inflammation. Bleomycin 118-127 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 84-89 12875966-1 2003 Mice with homozygous deletion of the plasminogen activator inhibitor-1 gene (PAI-1(-/-)) are relatively protected from bleomycin-induced pulmonary fibrosis. Bleomycin 119-128 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 37-70 12875966-1 2003 Mice with homozygous deletion of the plasminogen activator inhibitor-1 gene (PAI-1(-/-)) are relatively protected from bleomycin-induced pulmonary fibrosis. Bleomycin 119-128 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 77-82 12376355-1 2002 Plasminogen activator inhibitor-1 (PAI-1)-deficient transgenic mice have improved survival and less fibrosis after intratracheal bleomycin instillation. Bleomycin 129-138 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 0-33 8550840-0 1996 Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. Bleomycin 0-9 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 99-132 8550840-4 1996 2 wk after 0.075 U of bleomycin, the lungs of transgenic mice overexpressing PAI-1 contained significantly more hydroxyproline (118 +/- 8 micrograms) than littermate controls (70.5 +/- 8 micrograms, P < 0.005). Bleomycin 22-31 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 77-82 8550840-5 1996 3 wk after administration of a higher dose of bleomycin (0.15 U), the lung hydroxyproline content of mice completely deficient in PAI-1 (49 +/- 8 micrograms) was not significantly different (P = 0.63) than that of control animals receiving saline (37 +/- 1 micrograms), while hydroxyproline content was significantly increased in heterozygote (77 +/- 12 micrograms, P = 0.06) and wild-type (124 +/- 19 micrograms, P < 0.001) littermates. Bleomycin 46-55 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 130-135 33887217-7 2021 In vivo studies further show that deletion of PAI-1 in adult mice reduces p53, p21, and Bax proteins as well as apoptosis sensitivity in ATII cells but the opposite effects in lung fibroblasts, associated with an attenuation of lung fibrosis after bleomycin challenge. Bleomycin 248-257 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 46-51 25451236-5 2015 Upon bleomycin challenge, old mice experienced augmented PAI-1 induction and lung fibrosis as compared to young mice. Bleomycin 5-14 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 57-62 29777878-4 2018 Treatment of mice with bleomycin-induced PF using the PEI-C/siPAI-1 polyplexes resulted in a significant down-regulation of the PAI-1 expression and decreased collagen deposition in the lung. Bleomycin 23-32 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 62-67 28273432-10 2017 AEC-specific suppression of miR-34a inhibited bleomycin-induced p53, PAI-1, and apoptosis and prevented PF, whereas overexpression of precursor-miR-34a increased p53, PAI-1, and apoptosis in AECs of mice unexposed to bleomycin. Bleomycin 46-55 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 69-74 28722352-6 2017 In vivo studies, using ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, further support the role of PAI-1 in the activation of p53-p21-Rb cell cycle repression pathway, ATII cell senescence, and lung fibrosis induced by bleomycin. Bleomycin 268-277 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 148-153 25451236-6 2015 Most interestingly, we show that fewer (myo)fibroblasts underwent apoptosis and more (myo)fibroblasts with increased level of PAI-1 accumulated in the lung of old than in young mice after bleomycin challenge. Bleomycin 188-197 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 126-131 24024554-0 2014 Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury. Bleomycin 162-171 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 0-33 21734232-4 2011 We found that the vitronectin-binding capacity of PAI-1 was the primary determinant required for its ability to exacerbate lung scarring induced by intratracheal bleomycin administration. Bleomycin 162-171 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 50-55 23665346-2 2013 We used a mouse model of bleomycin (BLM)-induced lung injury to understand the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the regulation of alveolar epithelial injury. Bleomycin 25-34 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 165-198 21734232-5 2011 The critical role of the vitronectin-binding function of PAI-1 in fibrosis was confirmed in the bleomycin model using mice genetically modified to express the mutant PAI-1 proteins. Bleomycin 96-105 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 57-62 21239537-3 2011 Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages. Bleomycin 49-58 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 141-146 21239537-3 2011 Immunohistochemistry of lung tissue from a mouse bleomycin (BLM)-induced pulmonary fibrosis model revealed that expression of HIF-1alpha and PAI-1 was predominantly induced in alveolar macrophages. Bleomycin 60-63 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 141-146 19697510-4 2008 In this article, we describe recent advances concerning immunological aspects in the pathogenesis of bleomycin-induced murine scleroderma, laying stress on the involvement of interleukin-13 (IL-13) and plasminogen activator inhibitor-1 (PAI-1). Bleomycin 101-110 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 237-242 17331968-5 2007 Following bleomycin challenge, the strongest induction of tissue factor and plasminogen activator inhibitor (PAI)-1 mRNA expression was observed in alveolar macrophages (approximately 250- and 60-fold induction, respectively). Bleomycin 10-19 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 109-112 20501949-2 2010 We found that mice lacking plasminogen activation inhibitor-1 (PAI-1), which are protected from bleomycin-induced pulmonary fibrosis, exhibit lung overproduction of the antifibrotic lipid mediator prostaglandin E2 (PGE2). Bleomycin 96-105 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 27-61 20501949-2 2010 We found that mice lacking plasminogen activation inhibitor-1 (PAI-1), which are protected from bleomycin-induced pulmonary fibrosis, exhibit lung overproduction of the antifibrotic lipid mediator prostaglandin E2 (PGE2). Bleomycin 96-105 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 63-68 20388759-2 2010 In fact, PAI-1 knockout mice are protected from bleomycin-induced pulmonary fibrosis. Bleomycin 48-57 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 9-14 20388759-3 2010 This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis. Bleomycin 169-178 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 123-128 20388759-3 2010 This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis. Bleomycin 169-178 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 130-135 20388759-9 2010 The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs. Bleomycin 111-120 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 31-36 20388759-9 2010 The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs. Bleomycin 111-120 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 146-151